ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Table S3: Study defined phenotypic outcomes included in dataset
2
Study Disease/Trait
Number of variants
Percent
3
Epithelial ovarian cancer17123.1
4
Ovarian cancer7810.5
5
Cancer577.7
6
Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
354.7
7
High-grade serous ovarian cancer334.5
8
Paclitaxel disposition in epithelial ovarian cancer314.2
9
Progression free survival in epithelial ovarian cancer treated with carboplatin and paclitaxel
293.9
10
Breast cancer or ovarian cancer (pleiotropy)273.6
11
Cancer (pleiotropy)263.5
12
Ovarian cancer (MTAG)212.8
13
Serous invasive ovarian cancer192.6
14
Breast cancer, ovarian cancer or prostate cancer (pleiotropy)182.4
15
Carboplatin disposition in epthelial ovarian cancer182.4
16
Invasive epithelial ovarian cancer172.3
17
Progression free survival in serous epithelial ovarian cancer152
18
Progression free survival in epithelial ovarian cancer131.8
19
Low-grade serous and serous borderline ovarian cancer121.6
20
Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
101.4
21
Serous borderline ovarian cancer101.4
22
Waist-to-hip ratio or ovarian cancer (pleiotropy)81.1
23
Mucinous ovarian carcinoma81.1
24
Ovarian cancer in BRCA1 mutation carriers81.1
25
Waist-to-hip ratio adjusted for body mass index or ovarian cancer (pleiotropy)70.9
26
High-grade serous epithelial ovarian cancer70.9
27
Ovarian cancer or hospitalized COVID-19 (pleiotropy)60.8
28
Body mass index or ovarian cancer (pleiotropy)50.7
29
Ovarian cancer or COVID-19 infection (pleiotropy)50.7
30
Non-mucinous epithelial ovarian cancer40.5
31
Trunk fat ratio or ovarian cancer (pleiotropy)40.5
32
Ovarian cancer or critical COVID-19 (pleiotropy)40.5
33
Leg fat ratio or ovarian cancer (pleiotropy)30.4
34
Mucinous epithelial ovarian cancer30.4
35
Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)30.4
36
Response to carboplatin in ovarian cancer (MTT IC50)20.3
37
Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)20.3
38
Gluteofemoral adipose tissue or ovarian cancer (pleiotropy)20.3
39
Low-grade serous epithelial ovarian cancer20.3
40
Arm fat ratio or ovarian cancer (pleiotropy)20.3
41
Macroscopic residual disease after surgery in high grade serous ovarian cancer20.3
42
Ovarian cancer in BRCA2 mutation carriers20.3
43
Ovarian clear cell cancer20.3
44
Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)20.3
45
Endometrioid ovarian cancer10.1
46
Low-grade serous ovarian cancer10.1
47
Malignant neoplasm of ovary and other uterine adnexa (PheCode 184.1)10.1
48
Overall survival in ovarian cancer10.1
49
Malignant neoplasm of ovary (PheCode 184.11)10.1
50
Response to paclitaxel in ovarian cancer (MTT IC50)10.1
51
Visceral adipose tissue or ovarian cancer (pleiotropy)10.1
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100